Novartis Vaccines and Diagnostics Srl

Novartis Vaccines & Diagnostics, Gmbh

J. Craig Venter Institute

Novartis Ag

Chiron Corporation

Chiron S.r.l.

Glaxosmithkline Biologicals Sa

John Telford

Guido Grandi

Vega Masignani

Maria Scarselli

Claire M Fraser

Herve Tettelin

Rino Rappuoli

Paolo Costantino

Giuliano Bensi

Antonello Covacci

Massimo Bugnoli

Giovanni Macchia

Immaculada Margarit Y Ros

Domenico Maione

Francesco Berti

Mario Contorni

Renata Grifantini

Oretta Finco

Cira Daniela Rinaudo

Rino Chiron Corporation Rappuoli

The invention provides proteins from group B() and group A(), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Nucleic acids and proteins from streptococcus groups A and B

[object Object]

The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.

This application relates to Group B('GBS') vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.

The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group Bserotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.

The invention provides proteins from group B streptococcus () and group A streptococcus (), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Nucleic acids and proteins fromgroups A and B

Nucleic acids and proteins fromgroups A & B

Disclosed are severalantigens that are particularly suitable for immunisation purposes, particularly when used in combinations.

Immunogenic compositions for streptococcus pyogenes

Growing community of inventors

Monteriggioni, Italy

John Telford